Header Logo

Connection

ELIAS JOSEPH JABBOUR to Neoplasm, Residual

Back to Details
This is a "connection" page, showing publications ELIAS JOSEPH JABBOUR has written about Neoplasm, Residual.
ELIAS JOSEPH JABBOUR
Connection Strength
3.766
Neoplasm, Residual
  1. Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It. Curr Oncol Rep. 2017 Jan; 19(1):6.
    View in: PubMed
    Score: 0.378
  2. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 01 01; 123(2):294-302.
    View in: PubMed
    Score: 0.370
  3. Emerging therapy for the treatment of acute lymphoblastic leukemia. Expert Opin Emerg Drugs. 2010 Mar; 15(1):1-11.
    View in: PubMed
    Score: 0.235
  4. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol. 2024 Apr; 99(4):586-595.
    View in: PubMed
    Score: 0.155
  5. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024 Feb 01; 143(5):417-421.
    View in: PubMed
    Score: 0.154
  6. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022 07 12; 6(13):4006-4014.
    View in: PubMed
    Score: 0.139
  7. Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. Am J Hematol. 2022 Sep; 97(9):1135-1141.
    View in: PubMed
    Score: 0.138
  8. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv. 2021 12 14; 5(23):5415-5419.
    View in: PubMed
    Score: 0.133
  9. SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2022 02; 22(2):61-66.
    View in: PubMed
    Score: 0.130
  10. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020 01; 88:106283.
    View in: PubMed
    Score: 0.116
  11. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150.
    View in: PubMed
    Score: 0.115
  12. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. Am J Hematol. 2019 02; 94(2):257-265.
    View in: PubMed
    Score: 0.108
  13. SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2018 07; 18(7):439-446.
    View in: PubMed
    Score: 0.104
  14. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 11; 32(11):2388-2398.
    View in: PubMed
    Score: 0.103
  15. Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives. Clin Adv Hematol Oncol. 2018 Mar; 16(3):216-223.
    View in: PubMed
    Score: 0.102
  16. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. Future Oncol. 2017 Oct; 13(25):2233-2242.
    View in: PubMed
    Score: 0.098
  17. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol. 2017 Mar; 92(3):279-285.
    View in: PubMed
    Score: 0.095
  18. Adult Acute Lymphoblastic Leukemia. Mayo Clin Proc. 2016 Nov; 91(11):1645-1666.
    View in: PubMed
    Score: 0.093
  19. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017 02 01; 123(3):459-467.
    View in: PubMed
    Score: 0.093
  20. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017 02 01; 123(3):426-435.
    View in: PubMed
    Score: 0.093
  21. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820.
    View in: PubMed
    Score: 0.092
  22. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol. 2009 Aug 01; 27(22):3659-63.
    View in: PubMed
    Score: 0.056
  23. Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. Clin Lymphoma Myeloma. 2007 Mar; 7 Suppl 2:S51-7.
    View in: PubMed
    Score: 0.048
  24. Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv. 2023 07 11; 7(13):3284-3296.
    View in: PubMed
    Score: 0.037
  25. Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. 2023 08; 98(8):1196-1203.
    View in: PubMed
    Score: 0.037
  26. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease?(MRD) recurrence following MRD-negative remission. Am J Hematol. 2022 Nov; 97(11):E408-E411.
    View in: PubMed
    Score: 0.035
  27. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022 May; 9(5):e350-e360.
    View in: PubMed
    Score: 0.034
  28. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma. 2022 03; 63(3):672-675.
    View in: PubMed
    Score: 0.033
  29. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv. 2020 12 22; 4(24):6117-6126.
    View in: PubMed
    Score: 0.031
  30. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 03 15; 127(6):905-913.
    View in: PubMed
    Score: 0.031
  31. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Ann Hematol. 2020 Oct; 99(10):2215-2229.
    View in: PubMed
    Score: 0.030
  32. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1670-1677.
    View in: PubMed
    Score: 0.030
  33. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol. 2019 12; 94(12):1382-1387.
    View in: PubMed
    Score: 0.029
  34. Maintenance therapy in AML: The past, the present and the future. Am J Hematol. 2019 11; 94(11):1254-1265.
    View in: PubMed
    Score: 0.028
  35. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.
    View in: PubMed
    Score: 0.028
  36. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol. 2019 08; 186(4):538-548.
    View in: PubMed
    Score: 0.028
  37. "Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL. Clin Lymphoma Myeloma Leuk. 2018 05; 18(5):301-310.
    View in: PubMed
    Score: 0.026
  38. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica. 2017 10; 102(10):1709-1717.
    View in: PubMed
    Score: 0.025
  39. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol. 2017 Apr; 92(4):331-337.
    View in: PubMed
    Score: 0.024
  40. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M?nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 08; 91(8):819-23.
    View in: PubMed
    Score: 0.023
  41. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016 07 28; 128(4):504-7.
    View in: PubMed
    Score: 0.023
  42. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016 Jun; 91(4):385-9.
    View in: PubMed
    Score: 0.022
  43. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400.
    View in: PubMed
    Score: 0.022
  44. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64.
    View in: PubMed
    Score: 0.022
  45. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015 Jun 15; 21(12):2704-14.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.